Tradestie Institutional Equity Comparison Engine · Market Close Nov 20, 2026

PEN vs NMTC: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

PEN Wins Head-to-Head Institutional Verdict (5–1 across 6 Pillars · 9–1 Matrix Metrics)

PEN Overall Winner 6-Pillar Tally: PEN 5 – 1 NMTC Matrix Metrics: PEN 9 – 1 NMTC

As of Nov 20, 2026, Penumbra, Inc. (PEN) is the stronger overall head-to-head candidate over NeuroOne Medical Technologies Corporation (NMTC) in the Tradestie Institutional Equity Comparison Engine, winning 9–1 core matrix metrics and 5–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Profitability & Quality, Balance Sheet & Cash Flow). PEN carries a Unified Composite Score of 52.2/100 (HOLD) at $319.12 (53.1x Forward P/E, 12.1% operating margin), whereas NMTC carries 45.5/100 (HOLD) at $0.65 (N/M Forward P/E, -63.4% operating margin).

  • Technical & Structure Timing Caution: PEN is currently in a Weinstein Distribution regime near a flattening 50-day moving average (RSI 45.0); meanwhile NMTC is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 31.2). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About PEN vs NMTC
PEN NYSE Head-to-Head Winner
Penumbra, Inc.
Surgical & Medical Instruments & Apparatus
$319.12
-0.28% 1D
Market Cap $12.6B
TTM Revenue $1.56B
Forward P/E 53.1x
Beta / 30D Vol 0.10β · 10% Vol
Unified Composite Score
52.2 / 100 HOLD
Tech 55.0 Fund 56.0 Flow 63.0 Mom 46.0
Weinstein Technical Phase Distribution · Trim / tighten stop
Price near a flattening SMA50 (slope -0.2%) with fading momentum, RSI 45
RSI-14: 45.0 · SMA20: $320.94 · SMA50: $320.21
NMTC NASDAQ
NeuroOne Medical Technologies Corporation Common Stock
Surgical & Medical Instruments & Apparatus
$0.65
-3.38% 1D
Market Cap $6.1M
TTM Revenue $12M
Forward P/E N/M
Beta / 30D Vol 1.55β · 105% Vol
Unified Composite Score
45.5 / 100 HOLD
Tech 33.0 Fund 51.0 Flow 60.0 Mom 64.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -28.4%), weak momentum, RSI 31
RSI-14: 31.2 · SMA20: $0.83 · SMA50: $1.03

6-Pillar Scorecard Institutional Category Breakdown (PEN 5 – 1 NMTC)

Columns: Metric · PEN · NMTC
1. Valuation Multiples PEN
Forward P/E 53.1x N/M
Trailing P/E 80.6x N/M
PEG Ratio 3.61x N/M
EV / Revenue 8.1x 0.3x
2. Growth & Scale NMTC
Revenue Growth (YoY) +15.6% +16.3%
Earnings Growth (YoY) -8.5% +0.0%
TTM Revenue (USD) $1.56B $12M
Market Cap $12.6B $6.1M
3. Profitability & Quality PEN
Gross Margin 68.0% 23.0%
Operating Margin 12.1% -63.4%
Net Profit Margin 10.1% -59.7%
Return on Equity (ROE) 10.7% -124.7%
4. Balance Sheet & Cash Flow PEN
Cash Generation (TTM) $200M -$7.6M
Cash Flow Margin 12.8% -60.7%
Net Cash / Leverage $45M Net Cash $2.6M Net Cash
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning PEN
Options Structure Phase UNCLASSIFIED UNCLASSIFIED
Current IV / %ile 207.7% (96th %ile) N/A (N/A)
Put/Call OI Skew N/A N/A
OBV Trend / Tech Phase NEUTRAL · Distribution NEUTRAL · Markdown
6. R&D & Supply-Chain Moat PEN
OpEx & R&D Intensity 55.9% of Rev ($872M) N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Medical Devices Operator Medical Devices Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: PEN (9) vs NMTC (1)
Institutional Metric PEN NMTC Criterion Row Edge
Market Capitalization
Scale
$12.6B $6.1M Larger Scale PEN
Trailing P/E Ratio
Valuation
80.6x N/M Lower Multiple PEN
Forward P/E Ratio
Valuation
53.1x N/M Lower Multiple PEN
Revenue Growth (YoY)
Growth
+15.6% +16.3% Higher Growth NMTC
Operating Margin (TTM)
Profitability
12.1% -63.4% Higher Margin PEN
Net Profit Margin
Profitability
10.1% -59.7% Higher Margin PEN
Return on Equity (ROE)
Capital Efficiency
10.7% -124.7% Higher ROE PEN
52-Week Range Position
Momentum
50% ($277–$362) 2% ($1–$5) Stronger Trend PEN
Beta / 30D Volatility
Risk Regime
0.10β · 10% Vol 1.55β · 105% Vol Lower Realized Risk PEN
Unified Institutional Score
Composite Signal
52.2 / 100 (HOLD) 45.5 / 100 (HOLD) Higher Composite PEN
Trailing 12M Revenue (USD)
Operating Scale
$1.56B $12M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
68.0% 23.0% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
3.61x PEG · 8.1x EV/Rev N/M PEG · 0.3x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
$200M ($45M Net Cash) -$7.6M ($2.6M Net Cash) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon PEN +31.66 pp
PEN: -1.8% · NMTC: -33.46%
3M Horizon PEN +68.1 pp
PEN: -1.43% · NMTC: -69.53%
6M Horizon PEN +79.42 pp
PEN: -2.91% · NMTC: -82.33%
1Y Horizon PEN +9.21 pp
PEN: +12.7% · NMTC: +3.49%

Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant USD Revenue & Operating Margin (%)
Period PEN Revenue NMTC Revenue PEN Op. Margin NMTC Op. Margin Margin Leader
FY2018 $440M N/A -0.2% N/A PEN
FY2019 $550M N/A 8.7% N/A PEN
FY2020 $560M N/A -6.9% N/A PEN
FY2021 $750M $0M -1.0% -5735.9% PEN
FY2022 $850M $0M 0.7% -5860.2% PEN
FY2023 $1.06B $0M 6.9% -612.3% PEN
FY2024 $1.19B $0M 0.8% -344.3% PEN
FY2025 $1.40B $10M 13.5% -46.5% PEN

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
PEN UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV 207.7%
IV Percentile 96th %ile
Put/Call OI Skew N/A
IV Regime Extreme (>80th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BEARISH
OBV Flow NEUTRAL
Exact PEN Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
NMTC UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact NMTC Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
LIVE OPTIONS CHAIN · T+5 TRADING DAY HORIZON Spot $319.69 · IV 30.1%

PEN Simulated 5-Day Option Payoffs vs. Owning 100 Shares ($31,969)

Compare $31,969 in 100-share capital outlay against risk-defined 5-day vertical spreads, put-wall income, and 3-leg structures at 30.1% ATM IV.

PUT-WALL MONTHLY INCOME Liq B

Dec 18 $290 / $260 Bull Put Spread

Sell 1x $290P · Buy 1x $260P · 31d

Net Entry $140 Credit
Max Credit / Yield +$140 (+4.9% RoM)
Max Risk / Buffer -9.7% Cushion ($2,860 Mgn)
5d Edge & Liquidity 81% PoP · Liq B
Simulate 5-Day Payoff →
5-DAY DOWNSIDE SPREAD Liq B

Dec 18 $320 / $300 Bear Put Spread

Buy 1x $320P · Sell 1x $300P · 31d

Net Entry $750 Debit
T+5d @ -5% Drop +$425 (+57%)
Max Risk / Buffer $750 Capped
5d Edge & Liquidity 1.0x R:R · Liq B
Simulate 5-Day Payoff →

Simulated T+5 trading day payoffs use live option midpoints, bid-ask spread adjustments, and implied volatility skew for educational scenario modeling only — not personalized investment advice. Options involve substantial risk.

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
PEN Moat Profile Cyclical / Execution-Driven Positioning
Medical Devices Operator
Competes within the Medical Devices value chain with $12.6B market capitalization and 12.1% operating margin.
OpEx & R&D Reinvestment 55.9% of Rev ($872M)
90D Engineering Disclosures 0 Published
NMTC Moat Profile Cyclical / Execution-Driven Positioning
Medical Devices Operator
Competes within the Medical Devices value chain with $6.1M market capitalization and -63.4% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ PEN vs NMTC Key Questions & Quantitative Answers

As of Nov 20, 2026, Penumbra, Inc. (PEN) is the stronger overall head-to-head candidate over NeuroOne Medical Technologies Corporation (NMTC) in the Tradestie Institutional Equity Comparison Engine, winning 9–1 core matrix metrics and 5–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Profitability & Quality, Balance Sheet & Cash Flow). PEN carries a Unified Composite Score of 52.2/100 (HOLD) at $319.12 (53.1x Forward P/E, 12.1% operating margin), whereas NMTC carries 45.5/100 (HOLD) at $0.65 (N/M Forward P/E, -63.4% operating margin). Technical & Structure Timing Caution: PEN is currently in a Weinstein Distribution regime near a flattening 50-day moving average (RSI 45.0); meanwhile NMTC is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 31.2). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

NMTC leads the Growth & Scale pillar: PEN posts +15.6% YoY revenue growth and -8.5% YoY earnings growth on $1.56B TTM revenue (68.0% gross margin, 12.1% operating margin), compared with NMTC at +16.3% YoY revenue growth and +0.0% YoY earnings growth on $12M TTM revenue (23.0% gross margin, -63.4% operating margin). Across the 8-period historical trajectory (FY2018 to FY2025), PEN cumulative revenue shifted +218.2% while NMTC shifted N/A. In operating R&D and SG&A reinvestment, PEN deploys 55.9% of Rev ($872M) (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for NMTC.

PEN screens cheaper on headline valuation multiples. PEN trades at 53.1x Forward P/E, 80.6x Trailing P/E, 3.61x PEG, and 8.1x EV/Revenue (12.8% FCF margin), whereas NMTC trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 0.3x EV/Revenue (-60.7% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against PEN (10.7% ROE) versus NMTC (-124.7% ROE) capital efficiency.

In options market volatility and institutional positioning, PEN carries 207.7% implied volatility (96th %ile, Extreme (>80th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.10β · 10% Vol realized risk). By comparison, NMTC carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.55β · 105% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 20, 2026. For educational research only; not investment advice.